Tevogen (TVGN) Retained Earnings (2021 - 2026)
Tevogen's (TVGN) quarterly Retained Earnings came in at -$145.1 million in Q1 2026, down 17.26% on a YoY basis from -$175.4 million in Q1 2025, and down 3.9% quarter-over-quarter from -$139.7 million in Q4 2025.
Analysis
Tevogen (TVGN) Retained Earnings (2021 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Retained Earnings for 6 consecutive years, with -$145.1 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 17.26% year-over-year to -$145.1 million; the trailing twelve-month figure through Mar 2026 stood at -$145.1 million (down 17.26% YoY), and the FY2025 full-year result was -$139.7 million, down 23.17% from the prior year.
- Retained Earnings declined to -$145.1 million in Q1 2026 per TVGN's latest filing, from -$139.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$14.0 million in Q2 2022 and bottomed at -$145.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$75.4 million across 5 years, with a median of -$98.1 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings fell 3.9% in 2022, then sank 574.06% in 2023.
- Over 5 years, Retained Earnings stood at -$14.8 million in 2022, then tumbled by 574.06% to -$99.7 million in 2023, then declined by 13.77% to -$113.4 million in 2024, then retreated by 23.17% to -$139.7 million in 2025, then fell by 3.9% to -$145.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$145.1 million, -$139.7 million, and -$135.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 1.23 Bn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -2.16 Bn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 3.62 Bn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 1.23 Bn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 1.84 Bn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 2.93 Bn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 2.37 Bn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | -4.55 Bn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | -380.40 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -145.11 Mn |
| Dec 31, 2025 | -139.66 Mn |
| Sep 30, 2025 | -134.98 Mn |
| Jun 30, 2025 | -129.26 Mn |
| Mar 31, 2025 | -123.75 Mn |
| Dec 31, 2024 | -113.39 Mn |
| Sep 30, 2024 | -103.94 Mn |
| Jun 30, 2024 | -98.06 Mn |
| Mar 31, 2024 | -88.39 Mn |
| Dec 31, 2023 | -99.66 Mn |
| Sep 30, 2023 | -16.16 Mn |
| Jun 30, 2023 | -15.55 Mn |
| Mar 31, 2023 | -15.33 Mn |
| Dec 31, 2022 | -14.78 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | -14.05 Mn |
| Mar 31, 2022 | -14.26 Mn |
| Dec 31, 2021 | -14.23 Mn |